DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Thalomid (Thalidomide) - Published Studies

 
 



Thalomid Related Published Studies

Well-designed clinical trials related to Thalomid (Thalidomide)

Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. [2011.12.01]

Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma. [2011.10]

Poor tolerability of thalidomide in end-stage oesophageal cancer. [2011.09]

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. [2011.08.04]

Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. [2011.03.10]

Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. [2011.01]

A prospective randomised phase II trial of thalidomide with carboplatin compared with carboplatin alone as a first-line therapy in women with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis. [2011]

Poor tolerability of thalidomide in end-stage oesophageal cancer. [2011]

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. [2010.12.18]

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. [2010.12.01]

Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. [2010.12]

A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. [2010.11]

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. [2010.10]

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. [2010.09.02]

A randomized double-blind, positive-control trial of topical thalidomide in erosive oral lichen planus. [2010.08]

Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. [2010.07.01]

A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform. [2010.06]

A prospective double-blind, placebo-controlled study of thalidomide sensory symptoms in an elderly population with age-related macular degeneration. [2010.05]

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. [2010.02.11]

A randomized double-blind, positive-control trial of topical thalidomide in erosive oral lichen planus. [2010]

[The effect of thalidomide in preventing delayed nausea and vomiting induced by GP regimen of chemotherapy for non-small cell lung cancer] [2009.12]

Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer. [2009.11.01]

Thalidomide improves prevention of chemotherapy-induced gastrointestinal side effects following a modified FOLFOX7 regimen: results of a prospective randomized crossover study. [2009.11]

Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma. [2009.11]

Randomized Double-Blind Placebo-Controlled Trial of Thalidomide in Combination With Gemcitabine and Carboplatin in Advanced Non-Small-Cell Lung Cancer. [2009.10.13]

Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. [2009.08.05]

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. [2009.08.01]

Comparative efficacy of thalidomide and prednisolone in the treatment of moderate to severe erythema nodosum leprosum: a randomized study. [2009.08]

Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide. [2009.06.10]

Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. [2009.04.10]

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. [2009.04.09]

[Randomized study of thalidomide combined with vinorelbine and cisplatin chemotherapy for the treatment of advanced non-small cell lung cancer] [2009.04]

A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. [2009.03]

Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study. [2009.03]

Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. [2009.02]

Randomized Trial of Adjuvant Thalidomide Versus Observation in Patients With Completely Resected High-Risk Renal Cell Carcinoma. [2008.10.22]

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. [2008.10.15]

Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. [2008.10.15]

A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. [2008.08]

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized, controlled trial. [2008.05.27]

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. [2008.05.01]

A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). [2008.05.01]

Prospective evaluation of quality of life and neurocognitive effects in patients with multiple brain metastases receiving whole-brain radiotherapy with or without thalidomide on Radiation Therapy Oncology Group (RTOG) trial 0118. [2008.05.01]

Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1. [2008.05]

Thalidomide causes sinus bradycardia in ALS. [2008.04]

Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study. [2008.03.31]

A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. [2008.03.30]

Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma. [2008.03.24]

Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. [2008.02.15]

A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. [2008.01.15]

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. [2007.10.06]

Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. [2007.09.01]

[Efficacy of transcatheter arterial chemoembolization combined thalidomide on hepatocellular carcinoma: a controlled randomized trial] [2007.08]

VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group. [2007.08]

Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. [2007.06]

Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy. [2007.06]

Randomized Phase II Trial of Thalidomide Alone versus Thalidomide Plus Interferon Alpha in Patients with Refractory Multiple Myeloma. [2007.04]

An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. [2007.01]

Effects of thalidomide treatment in heart failure patients. [2007]

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. [2006.11.15]

A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma. [2006.09]

Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study. [2006.08]

Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. [2006.07]

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. [2006.03.11]

Thalidomide and hematopoietic-cell transplantation for multiple myeloma. [2006.03.09]

Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma. [2006.02.20]

Immunological consequences of thalidomide treatment in Sjogren's syndrome. [2006.01]

A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma. [2005.09]

A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum. [2005.05]

Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. [2005.04]

Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. [2004.12.15]

Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. [2004.09]

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. [2004.07.01]

Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy. [2004.07]

A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma. [2004.07]

Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma. [2004.06]

Bradycardia during therapy for multiple myeloma with thalidomide. [2004.04.15]

Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study. [2004.04]

A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis. [2004.01.01]

Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. [2003.07.01]

[The short-term outcomes of patients with acute leukemia treated by thalidomide] [2003.05]

Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. [2003.03.01]

A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. [2003.03.01]

Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. [2002.11]

Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267. [2002.05.01]

Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251. AIDS Clinical Trials Group. [2001.10]

Thalidomide is distributed into human semen after oral dosing. [2001.10]

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. [2001.09.01]

Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: a randomized, double-blind, placebo-controlled trial. [2001.09]

A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. [2001.08]

Thalidomide neuropathy in patients treated for metastatic prostate cancer. [2001.08]

A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. [2001.07]

Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers. [2001.01.15]

Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. [2001]

Thalidomide for treatment of patients with chronic graft-versus-host disease. [2000.12.01]

Thalidomide for the treatment of AIDS-associated wasting. [2000.09.20]

Adjunctive thalidomide therapy of childhood tuberculous meningitis: possible anti-inflammatory role. [2000.08]

Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man. [2000.07]

Phase II evaluation of thalidomide in patients with metastatic breast cancer. [2000.07]

Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis. [2000.03]

Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women. [2000.01]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012